NOROMBY SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ENOXAPARIN SODIUM

から入手可能:

JUNO PHARMACEUTICALS CORP.

ATCコード:

B01AB05

INN（国際名）:

ENOXAPARIN

投薬量:

20MG

医薬品形態:

SOLUTION

構図:

ENOXAPARIN SODIUM 20MG

投与経路:

SUBCUTANEOUS

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

HEPARINS

製品概要:

Active ingredient group (AIG) number: 0131860001; AHFS:

認証ステータス:

APPROVED

承認日:

2020-10-14

製品の特徴

_ _
_NOROMBY (enoxaparin sodium solution for injection) _
_Page 1 of 91_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
NOROMBY
TM
Enoxaparin sodium
Solution for injection, 100 mg/mL, Subcutaneous or Intravenous Use
20 mg/0.2 mL
30 mg/0.3 mL
40 mg/0.4 mL
60 mg/0.6 mL
80 mg/0.8 mL
100 mg/mL
Pre-filled syringes
Pr
NOROMBY
TM HP
Enoxaparin sodium (High Potency)
Solution for injection, 150 mg/mL, Subcutaneous or Intravenous Use
120 mg/0.8 mL
150 mg/mL
Pre-filled syringes
BP Standard
ATC Code: B01AB05
Anticoagulant/Antithrombotic Agent
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, Ontario
L5N 2X7
Date of Initial Authorization:
October 14, 2020
Date of Revision:
March 28, 2023
Submission Control No: 268542
_ _
_NOROMBY (enoxaparin sodium solution for injection) _
_Page 2 of 91_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................................
4
1
INDICATIONS
...........................................................................................................................
4
1.1
Pediatrics
...............................................................................................................................
4
1.2
Geriatrics
...............................................................................................................................
4
2
CONTRAINDICATIONS
..............................................................................................................
5
4
DOSAGE AND ADMINISTRATION
..............................................................................................
5
4.1
Dosing Considerations
...........................................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment......................................................................
6
4.4
Administration
.......................................................................................................................
9
4.5
Misse